---
schema_version: "secwatch.filing_event.v1"
accession: "0001531048-23-000034"
form_type: "8-K"
ticker: null
cik: "0001531048"
company_name: "Inari Medical, Inc."
filed_at: "2023-11-15T23:59:59+00:00"
generated_at: "2026-06-08T02:21:31.291321+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Inari Medical closes $250M acquisition of LimFlow for CLTI limb salvage

## Summary
- Paid ~$238.4M at closing after adjustments; total upfront $250M cash from existing resources.
- Up to $165M in contingent milestones payable between 2025-2027 based on commercial/reimbursement goals.
- LimFlow is a pioneer in limb salvage for chronic limb-threatening ischemia (CLTI).
- Financial statements and pro forma results to be filed within 71 days of this report.

## SEC filing metadata
- accession: 0001531048-23-000034
- form_type: 8-K
- cik: 0001531048
- company_name: Inari Medical, Inc.
- filed_at: 2023-11-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1531048/000153104823000034/0001531048-23-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531048/000153104823000034/nari-20231115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001531048-23-000034
- JSON: https://secwatch.observer/filing/0001531048-23-000034.json
- Plain text: https://secwatch.observer/filing/0001531048-23-000034.txt

## Key facts
- M&A Transactions
  Inari Medical, Inc. completed an acquisition involving LimFlow S.A. for approximately $238.4 million (closed 2023-11-15).
  - Action: acquisition
  - Counterparty: LimFlow S.A.
  - Consideration: approximately $238.4 million
  - Closing: 2023-11-15
  source text: 15, 2023, the Company announced that it closed its acquisition of LimFlow (the “ Closing ”). Pursuant to the terms of the Purchase Agreement, the Company delivered approximately $238.4 million to the Sellers at the Closing, after accounting for working capital, indebtedness, cash and transaction expenses. The Company funded the transaction from its existing cash
  evidence_url: https://www.sec.gov/Archives/edgar/data/1531048/000153104823000034/0001531048-23-000034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.